Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 25, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 850,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,397.616 pence per share.
- Treasury Shares Held: 245,332,678 shares (post-transaction).
- Shares in Issue: 5,751,446,314 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 850,000 shares on January 25, 2007, which are now held in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
This filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is a compliance report confirming the execution of a share repurchase and the resulting capital structure figures required under the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,751,446,314) for calculating ownership thresholds under disclosure rules.
- Confirm the updated Treasury share count (245,332,678) for accurate fully diluted share count calculations.
- Note that this transaction was executed at a specific price of 1,397.616 pence per share.